65 studies found for:    "Pheochromocytoma"
Show Display Options
Rank Status Study
1 Completed Diagnosis and Treatment of Pheochromocytoma
Condition: Pheochromocytoma
Intervention:
2 Completed 131MIBG to Treat Malignant Pheochromocytoma
Condition: Pheochromocytoma
Interventions: Drug: [131]I-MIBG;   Drug: 6-[18F]Fluorodopamine;   Drug: [123]I-MIBG
3 Recruiting Diagnosis of Pheochromocytoma
Condition: Pheochromocytoma
Intervention:
4 Completed I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
Conditions: Neuroblastoma;   Pheochromocytoma
Intervention:
5 Recruiting MIBG for Refractory Neuroblastoma and Pheochromocytoma
Conditions: Relapsed Neuroblastoma;   Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131I-MIBG);   Drug: Potassium iodide solution;   Drug: G-CSF;   Procedure: hematopoietic stem cell infusion
6 Recruiting Phenoxybenzamine Versus Doxazosin in PCC Patients
Condition: Pheochromocytoma
Interventions: Drug: Phenoxybenzamine;   Drug: Doxazosin
7 Terminated Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention:
8 Temporarily not available A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma;   Pheochromocytoma
Intervention: Drug: 131-I-meta-iodobenzylguanidine
9 Recruiting First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Condition: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
Interventions: Drug: Sunitinib;   Drug: Placebo
10 Recruiting Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Drug: Sunitinib
11 Unknown  Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
12 Completed A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Radiation: 131I-MIBG
13 Completed
Has Results
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Ultratrace Iobenguane (MIBG) I 131
14 Active, not recruiting A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Radiation: Ultratrace® Iobenguane I131
15 Available Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Ultratrace Iobenguane I131
16 Active, not recruiting Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Axitinib (AG-013736)
17 Active, not recruiting Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation
Conditions: Paragangliomas;   Pheochromocytomas
Intervention: Other: PET-CT
18 Withdrawn Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Conditions: Phaeochromocytoma;   Paraganglioma
Interventions: Drug: Vandetanib;   Radiation: 131I-mIBG
19 Not yet recruiting Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Conditions: Malignant Adrenal Gland Pheochromocytoma;   Malignant Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Lenvatinib;   Other: Quality-of-Life Assessment
20 Completed Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma;   Essential Hypertension
Interventions: Other: plasma EM66 & CgA levels assessment;   Other: usual follow up with regular EM66 & Cga levels assessment

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.